Document is current
Any future updates will be listed below
-
Authors
Sirniö, Päivi
Elomaa, Hanna
Tuomisto, Anne
Äijälä, Ville K.
Karjalainen, Henna
Kastinen, Meeri
Tapiainen, Vilja V.
Sirkiä, Onni
Ahtiainen, Maarit
Helminen, Olli
Wirta, Erkki-Ville
Rintala, Jukka
Meriläinen, Sanna
Saarnio, Juha
Rautio, Tero
Seppälä, Toni T.
Böhm, Jan
Mecklin, Jukka-Pekka
Mäkinen, Markus J.
Väyrynen, Juha P. https://orcid.org/0000-0002-8683-2996
-
Funding
Funding for this research was provided by:
Finnish State Research Funding
Syöpäsäätiö (59-5619)
Emil Aaltosen Säätiö (220257P)
Suomen Lääketieteen Säätiö (6021)
Sigrid Juséliuksen Säätiö (230229)
University of Oulu
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 29 January 2025
First Online: 25 February 2025
Declarations
:
: T.T. Seppälä reports consultation fees from Tillots Pharma, Mehiläinen and Nouscom, being a co-owner and CEO of Healthfund Finland Ltd., and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. The other authors declare that they have no conflicts of interest.
: The study was performed according to the guidelines of the Declaration of Helsinki. For Cohort 1, the study was approved by the Regional medical research ethics committee of the Well-being services county of Central Finland (Dnro13U/2011, 1/2016, 8/2020, and 2/2023), the Finnish Medicines Agency (Fimea), and the Central Finland Biobank (BB23-0172). The need to obtain informed consent from the study patients was waived (FIMEA/2023/001573, 4/2023). For Cohort 2, the study was approved by the Regional medical research ethics committee of the Well-being services county of North Ostrobothnia (25/2002, 42/2005, 122/2009, and 37/2020), Fimea (FIMEA/2022/001941), and Biobank Borealis (BB-2017_1012). Patients signed an informed consent to participate.
